BBC
Virtus LifeSci Biotech Clinical Trls ETF
NAV as of
4 Week: 19.27 - 21.93
52 Week: 19.27 - 28.53
Latest Closing Price
19.62
Premium / Discount
-0.02
Expense Ratio
0.79%
Investment Objective
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -21.48 | 1.88 | -11.42 |
| 1 Day | 0.06 | 0.00 | 0.00 |
| 1 Week | -0.07 | 2.60 | -0.03 |
| 1 Month | -9.33 | 5.37 | -1.74 |
| 3 Months | -16.66 | 11.39 | -1.46 |
| 6 Months | -11.07 | 20.32 | -0.54 |
| 1 Year | -18.60 | 33.02 | -0.56 |
| 2 Years | -56.83 | 59.85 | -0.95 |
| 3 Years | -49.62 | 69.00 | -0.72 |
| 5 Years | -43.22 | 89.34 | -0.48 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 4.8732 | -36.5484 | 55.5596 | -17.4978 | 62.6004 | 30.8167 | -22.3478 | -35.3830 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 82.0000 | 100.0000 | 1.0000 | 99.0000 | 1.0000 | 28.0000 | 99.0000 | 91.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| N.A | ||
Portfolio Data
Total Number of Holdings: 115
Number of Bond Holdings: 0
Number of Equity Holdings: 114
Total Market Value: 8,847,278
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | Reata Pharmaceuticals Inc A | 2.6703 | 3,138 | 0 | 671,971 |
| 2 | Karyopharm Therapeutics Inc | 2.5322 | 44,969 | 0 | 637,211 |
| 3 | Achillion Pharmaceuticals Inc | 2.3256 | 92,017 | 0 | 585,228 |
| 4 | Ra Pharmaceuticals Inc | 2.2556 | 12,077 | 0 | 567,619 |
| 5 | Deciphera Pharmaceuticals Inc | 2.1951 | 11,967 | 0 | 552,397 |
| 6 | Immunogen Inc | 1.9243 | 129,652 | 0 | 484,250 |
| 7 | Allakos Inc | 1.7417 | 6,111 | 0 | 438,281 |
| 8 | BeiGene Ltd ADR | 1.6534 | 2,189 | 0 | 416,063 |
| 9 | Krystal Biotech Inc | 1.6128 | 9,432 | 0 | 405,859 |
| 10 | Arrowhead Pharmaceuticals Inc | 1.5697 | 9,942 | 0 | 394,996 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 0.00 |
| Large | 0.00 |
| Medium | 4.89 |
| Small | 19.96 |
| Micro | 72.01 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
5.2094
Price/Book*
2.2501
Price/Sales*
3.5444
Price/Cash Flow*
9.8245
Dividend Yield*
0.0000
Growth Measures
Long-Term Earnings
8.0000
Historical Earnings
18.5068
Sales Growth
31.2630
Cash-Flow Growth
8.7443
Book-Value Growth
-5.6832
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
